Amylin Sues Lilly Over Byetta Sales Plans

Law360, New York (May 16, 2011, 4:56 PM EDT) -- Amylin Pharmaceuticals Inc. said Monday it had sued Eli Lilly & Co. in California, claiming Lilly’s plans to use the same sales force to sell both Amylin’s diabetes treatment and a rival one are anti-competitive and in breach of a marketing deal.

Amylin joined forces with Lilly in 2002 to develop and commercialize exenatide, a treatment for Type 2 diabetes currently marketed as Byetta. But when Lilly also announced a global alliance with Boehringer Ingelheim GmbH to develop and commercialize the rival diabetes treatment linagliptin, and...
To view the full article, register now.